Background

Esophageal cancer patients undergo short-term neoadjuvant chemotherapy or radiation therapy to reduce tumor size and suppress micro-metastasis before surgery. Cancer treatment research has long focused on tracking genomic changes in cancer cells that respond to or survive drugs. Normal tissues surrounding the tumor have often been regarded merely as victims of treatment toxicity or as control groups.

Human normal epithelial tissue is a space where somatic mutations naturally accumulate with age. Due to aging and chronic stimulation, various cell clones with genetic variations are positioned like a mosaic within the normal esophageal mucosa. However, it remained unclear what specific genetic selection pressures high-dose therapies administered before surgery exert on normal epithelial cell clusters rather than cancer cells. This background necessitated research to identify how treatment stress reshapes the genomic landscape of normal cells.

Key Findings

The research team performed deep genomic analysis of normal esophageal epithelial tissue from cancer patients who received preoperative neoadjuvant therapy. Short-term chemotherapy and radiation therapy did not leave distinct new mutational signatures in the normal esophageal mucosa. In other words, unique substitution patterns resulting from direct DNA base damage by specific drugs were not imprinted on a large scale.

However, the evolutionary selection pressure induced by the treatment was clearly reflected in the composition of cell clones. In normal esophageal tissue that underwent treatment, clones carrying mutations in DNA damage response (DDR), human leukocyte antigen (HLA), and kinase-related genes were strongly enriched. Positive selection occurred, where only specific normal cells possessing genotypes capable of enduring or evading the cell death signals induced by the treatment survived and expanded their populations.

These findings suggest a new methodology for tracking treatment resistance mechanisms. Previous studies have struggled significantly to identify resistance-causing genes within tumor tissues, where countless mutations are intertwined. In contrast, by analyzing normal tissues with relatively intact genomic structures, it became possible to much more clearly distinguish the key genes and biochemical pathways that allow cells to overcome anti-cancer attacks.

Significance and Outlook

The normal tissue of treated patients has been re-evaluated as a precise compass for searching for drug-resistance genes. Due to extreme genomic instability, cancer cells produce numerous passenger mutations unrelated to function, making it difficult to distinguish true resistance genes. Normal epithelial cells maintain genomic stability, thereby fully reflecting the pure selection pressure exerted by the treatment. This opens a path to rapidly identify genes that induce resistance by sequencing normal tissue alone.

This is expected to have a direct impact on the fields of new drug development and biomarker discovery. By backtracking the genotypes of normal cell clones that survived treatment, molecular pathways conferring resistance to cytotoxic therapy can be predicted in advance. However, the fact that this study focused on esophageal tissue from patients who had undergone short-term neoadjuvant therapy is a limitation to be addressed in future studies. Follow-up verification is required to determine if the same clonal selection phenomenon occurs in patient groups receiving long-term chemotherapy or in other epithelial tissues such as the lungs and intestines.